ImmuSAFE™ COVID Tests Product Range

The road to economic recovery

Implementing the Sengenics ImmuSAFE™ biochip for mass population screening within countries, organisations and companies can result in immediate macroeconomic, social and public health benefits including:

National economy

ImmuSAFE™ certified individuals may be able to get back to work and start to contribute towards the normalisation of the economy

Private sector

Companies are able to restart operations with ImmuSAFE™ certified employees with the possibility that the risk of reinfection and transmission may be much lower

Business travel and tourism

ImmuSAFE™ can be used to confirm whether an individual has had COVID-19 and recovered. Assess and confirm a traveler’s health risk and vaccination or COVID-19 infection status prior to travel

ImmuSAFE™ is the world’s first multivalent biochip-based quantitative screening test for COVID-19

Both the ImmuSAFE™ COVID and ImmuSAFE™ COVID+ tests enable high-throughput fully quantitative screening of total immunoglobulin and IgG:IgM ratios towards multiple SARS-CoV-2 antigens, antigens from 5 other Coronaviruses including SARS, MERS as well as Influenza A and B HA antigen subtypes. All viral antigens on the ImmuSAFE™ biochips were expressed using KREX, which ensures that the proteins on the biochip are correctly folded which is critical for maximising true positive results.

By measuring antibodies to multiple viral antigens in a fully quantitative manner, ImmuSAFE™ results are able to determine both the stage of infection as well as the level of antibodies, down to picogram level sensitivity. This is important to determine whether or not an individual has a protective level of antibodies.

In addition to this, as more than 90% of individuals referred to hospitals with suspected COVID-19 actually have flu, the ImmuSAFE™ tests will results are far more likely to be accurate as it also includes multiple Influenza A and B antigens to determine whether an individual has been infected with COVID-19.

Product Description


Code Product Description Order Link
39508H ImmuSAFE™ COVID Protein Microarray
Contains SARS-CoV-2 Spike, Nucleocapsid and Envelope antigens. All antigens are expressed using the patented KREX functional proteomics technology developed by Sengenics. Viral antigens are full-length, correctly folded, functional, with both conformational and non-conformational antibody binding sites preserved. Key application is high-throughput diagnostics and screening. Requires liquid handling robot for sample handling.
Request
a Quote
39508V ImmuSAFE™ COVID+ Protein Microarray
Contains SARS-CoV-2 Spike, Nucleocapsid and Envelope antigens, and antigens from 5 other Coronaviruses including SARS, MERS, 229E, NL63, HKU1 and Influenza A and B HA antigen subtypes. All antigens are expressed using the patented KREX functional proteomics technology developed by Sengenics. Viral antigens are full-length, correctly folded, functional, with both conformational and non-conformational antibody binding sites preserved. Key application is mass screening of populations for Immunity certification purposes.
Request
a Quote
39508R ImmuSAFE™ Respiratory Virus Protein Microarray
Contains SARS-CoV-2 Spike, Nucleocapsid and Envelope antigens, and antigens from more than 13 Coronaviruses including SARS, MERS, 229E, NL63, HKU1 and multiple Influenza A and B HA antigen subtypes. All antigens are expressed using the patented KREX functional proteomics technology developed by Sengenics. Viral antigens are full-length, correctly folded, functional, with both conformational and non-conformational antibody binding sites preserved. Key application is for research and development purposes.
Request
a Quote

Technical details of main antigens


Code Product Description Data Sheet Order Link
39501 Recombinant SARS-CoV-2 Nucleocapsid Protein
GenBank accession code: MN908947.3, Protein sequence length (aa): 419
Download
Data Sheet
Request
a Quote
39502 Recombinant SARS-CoV-2 Spike Protein
GenBank accession code: YP_009724390.1, Protein sequence length (aa): 1273
Download
Data Sheet
Request
a Quote
39503 Recombinant SARS-CoV-2 Spike (R682S) Protein
GenBank accession code: YP_009724390.1, Protein sequence length (aa): 1273
Download
Data Sheet
Request
a Quote
39504 Recombinant SARS-CoV-2 Envelope Protein
GenBank accession code: QHD43418.1, Protein sequence length (aa): 75
Download
Data Sheet
Request
a Quote
39505 Recombinant SARS-CoV (2004) Nucleocapsid Protein
GenBank accession code: NP_828858.1, Protein sequence length (aa): 422
Download
Data Sheet
Request
a Quote
39506 Recombinant MERS-CoV Nucleocapsid Protein
GenBank accession code: AKQ21082.1, Protein sequence length (aa): 413
Download
Data Sheet
Request
a Quote
39507A Recombinant CoV-HKU1 Nucleocapsid Protein
GenBank accession code: ABD75533.1, Protein sequence length (aa): 441
Download
Data Sheet
Request
a Quote
39507B Recombinant CoV-229E Nucleocapsid Protein
GenBank accession code: AGW80945.1, Protein sequence length (aa): 389
Download
Data Sheet
Request
a Quote
39507C Recombinant CoV-NL63 Nucleocapsid Protein
GenBank accession code: AFD98817.1, Protein sequence length (aa): 377
Download
Data Sheet
Request
a Quote


FEATURED COVID-19 PRODUCTS

COVID Antigens

Recombinant SARS-CoV-2 Nucleocapsid and Spike Protein lysates expressed in baculovirus expression system using the patented KREX™ functional proteomics technology

COVID Antigen Array

Contains full-length, correctly folded and functional human SARS-CoV-2 and antigens from other respiratory viruses including influenza, SARS
and MERS

COVID Microtitre Plate

Contains full-length, correctly folded and functional human SARS-CoV-2 and antigens from other respiratory viruses including influenza, SARS
and MERS

DOWNLOADS

Resources to access our technology

FAQs

Your technical questions – answered

SOLUTIONS

One technology – endless possibilities

Sengenics - Functional Proteomics | Krex Technology | Protein Array Supplier

Sengenics is a functional proteomics company that leverages its patented KREX technology for production of full-length, correctly folded and functional proteins. The key application of KREX is the discovery of autoantibody biomarkers for two core medical use cases:  stratification of patients undergoing treatment with autoimmune or cancer drugs and identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Find Us On:

2008 – 2020© Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361 

X